Table 4. Clinical and functional characteristics of the IPF patients with positive or negative cultures of fibroblasts.
Fibroblasts (+) | Fibroblasts (−) | P value | |
Number of patients (%) | 12 (46%) | 14 (54%) | |
Age | 75 [66–84] | 72 [56–84] | 0.4 |
Gender (Male) | 7 (58) | 12 (72) | 0.06 |
Smoker (ever) | 8 (66) | 8 (57) | 0.7 |
Exacerbation | 2 | 1 | 0.58 |
Delay since diagnosis (days) | 18 [0–236] | 7 [0–655] | 0.74 |
Death or lung transplant during follow up | 4 (33) | 4 (42) | 1 |
Oral steroids | 4 (33) | 2 (14) | 0.36 |
CCL2 (pg/ml) | 269 [102–1033] | 64 [0–341] | 0.02 |
CXCL12 (pg/ml) | 0 [0–22.7] | 0 [0–0] | 0.54 |
PaO2 (mm Hg) | 76 [50–101] | 77 [45–91] | 0.8 |
VC (% pred) | 79 [40–101] | 67 [34–108] | 0.57 |
DLCO (% pred) | 35 [15–59] | 35 [27–91] | 0.36 |
Pulmonary Hypertension | 1 | 2 | 1 |
HRCT fibrosis score | 8 [4]–[13] | 8 [6]–[14] | 0.56 |
Detection of Fibrocytes in BAL | 5 (41) | 9 (64) | 0.43 |
Data are expressed as median [range] or N (%).